Abstract
Carbapenems remain the main therapeutic option for treatment of Acinetobacter baumannii infections. Unfortunately, carbapenenem-resistant A. baumannii have emerged worldwide. Control of outbreaks caused by carbapenem-resistant A. baumannii is rarely achieved due to pathogen´s intrinsic characteristics. Among A. baumannii isolates, the production of ²-lactamase constitutes the most frequen…